BioPharma Resources

Drug Trial Radar · NCT05276297

A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy

A Phase 2, Single-blinded, Randomised, Controlled Multi-country Study to Evaluate the Safety, Reactogenicity, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide (ASO) Against Chronic Hepatitis B (CHB) Followed by Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy

Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 174 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

174

Actual

Start

Mar 22, 2022

Primary completion

Aug 5, 2025

Study completion Aug 5, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety, efficacy and immune response following the sequential treatment of GlaxoSmithKline's (GSK) ASO compound (GSK3228836) and CHB-TI (GSK3528869A) in participants 18 to 65 years stable on NA treatment for CHB. The aim is to quantify the efficacy of sequential therapy as well as to determine an added value of sequential therapy over GSK3228836 therapy in CHB patients treated with NAs. In addition, the study will assess the effect of different treatment durations of GSK3228836 (12 or 24 weeks) prior to initiating GSK3528869A treatment.

Conditions

  • Hepatitis B, Chronic

Interventions

  • GSK3228836Drug

    2 doses of GSK3228836 study intervention administered subcutaneously once per week for 12 weeks (Day 1 up to Day 78) to participants in ASO12-TI and ASO12 groups, or for 24 weeks (Day 1 up to Day 162) to participants in ASO24-TI and ASO24 groups, plus loading doses administered at Day 4 and Day 11 (2 doses each day) to participants in all groups during Treatment 1 period.

  • GSK3528869ABiological

    The GSK3528869A chronic Hepatitis B targeted immunotherapy (CHB-TI) consisting of 4 doses administered intramuscularly as follows: * 1 dose of the Chimpanzee adenovectored HBV vaccine (ChAd155-hIi-HBV) at Day 1 of Treatment 2 period. * 1 dose of the Modified Vaccinia Virus Ankara HBV vaccine (MVA-HBV) at Day 57 of Treatment 2 period. * 2 subsequent doses of the AS01B-4-adjuvanted HBc-HBs proteins (HBc-HBs/AS01B-4) administered at Day 113 and Day 169 of Treatment 2 period.

  • ControlDrug

    4 doses of non-active control administered intramuscularly in the deltoid region of the non-dominant arm at Days 1, 57, 113 and 169 to participants in ASO24 and ASO12 control groups during Treatment 2 period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting any grade 3 adverse event (AE) from first dose of GSK3228836 up to study endTime frame: From first dose of GSK3228836 (Treatment 1 -Day 1) up to study end (Treatment 2-Day 505/Day 673/Day 841)
  2. Percentage of participants reporting any serious adverse event (SAE) from first dose of GSK3228836 up to study endTime frame: From first dose of GSK3228836 (Treatment 1-Day 1) up to study end (Treatment 2-Day 505/Day 673/Day 841)
  3. Percentage of participants reporting any adverse events of special interest (AESIs) grade 3 or higher from first dose of GSK3228836 up to study endTime frame: From first dose of GSK3228836 (Treatment 1-Day 1) up to study end (Treatment 2-Day 505/Day 673/Day 841)
  4. Percentage of participants who achieve sustained virologic response (SVR) for 24 weeks after the planned end of active treatment in the absence of rescue medication, and difference between treatment arms (corresponding to GSK3228836 regimens)Time frame: For up to 24 weeks after the planned end of active treatment (planned end of active treatment = Treatment 1-Day 78 for ASO12 group, Treatment 1-Day 162 for ASO24 group and Treatment 2-Day 169 for ASO12-TI and ASO24-TI groups)

Locations

51 sites in 15 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Sliven, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Veliko Tarnovo, Bulgaria

  • GSK Investigational Site

    Vratsa, Bulgaria

  • GSK Investigational Site

    Clichy, France

  • GSK Investigational Site

    Créteil, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Strasbourg, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Frankfurt, Germany

  • GSK Investigational Site

    Leipzig, Germany

  • GSK Investigational Site

    Pokfulam, Hong Kong

  • GSK Investigational Site

    Bergamo, Italy

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Roma, Italy

  • GSK Investigational Site

    Rozzano MI, Italy

  • GSK Investigational Site

    Makati City, Philippines

  • GSK Investigational Site

    Pasig, Philippines

  • GSK Investigational Site

    Krakow, Poland

  • GSK Investigational Site

    Łańcut, Poland

  • GSK Investigational Site

    Mysłowice, Poland

  • GSK Investigational Site

    Cluj-Napoca, Romania

  • GSK Investigational Site

    Craiova Dolj, Romania

  • GSK Investigational Site

    Singapore, Singapore

  • GSK Investigational Site

    Singapore, Singapore

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Santander, Spain

  • GSK Investigational Site

    Seville, Spain

  • GSK Investigational Site

    Vigo, Spain

  • GSK Investigational Site

    Chiayi City, Taiwan

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.